Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth

Cancer Gene Therapy

Volumn 14, Issue 1, 2007, Pages 19-29

  Cordelier, P ^a   Bienvenu, C ^a   Lulka, H ^a   Marrache, F ^a   Bouisson, M ^a   Openheim, A ^b   Strayer, D S ^c   Vaysse, N ^a   Pradayrol, L ^a   Buscail, L ^a  

^a INSERM   (France)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Pancreatic adenocarcinoma; sst2 tumor suppressor gene; SV40 vectors

Indexed keywords

ADENOVIRUS VECTOR; POLYETHYLENEIMINE; SIMIAN VIRUS 40 VECTOR; SOMATOSTATIN RECEPTOR 2; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; SIMIAN VIRUS 40; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

BASE SEQUENCE; CELL LINE, TUMOR; DEFECTIVE VIRUSES; DNA PRIMERS; GENE TRANSFER TECHNIQUES; HUMANS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; SIMIAN VIRUS 40; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 33845615952     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700987     Document Type: Article

References (71)

1. Safioleas MC, Moulakakis KG. Pancreatic cancer today. Hepatogastroenterology 2004; 51: 862-868.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
3. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349: 485-489.
4. Jafari M, Abbruzzese JL, Goldstein D, Carroll S, Apte M, Keogh G. Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force Modern management of pancreatic carcinoma. Surg Oncol Clin N Am 2004; 13: 751-760.
5. Kulke MH. Metastatic pancreatic cancer. Curr Treat Options Oncol 2002; 3: 449-457.
6. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
7. Tsai JY, Iannitti DA, Safran H. Combined modality therapy for pancreatic cancer. Semin Oncol 2003; 30: 71-79.
8. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Front Biosci 1998; 3: E214-E225.
9. McClane SJ, Chirmule N, Burke CV, Raper SE. Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum Gene Ther 1997; 8: 2207-2216.
10. McClane SJ, Hamilton TE, Burke CV, Raper SE. Functional consequences of adenovirus-mediated murine pancreatic gene transfer. Hum Gene Ther 1997; 8: 739-746.
11. Zhang N, Schroppel B, Chen D, Fu S, Hudkins KL, Zhang H et al. Adenovirus transduction induces expression of multiple chemokines and chemokine receptors in murine beta cells and pancreatic islets. Am J Transplant 2003; 3: 1230-1241.
12. Pearson AS, Koch PE, Atkinson N, Xiong M, Finberg RW, Roth JA et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 4208-4213.
13. Strayer DS, Cordelier P, Kondo R, Liu B, Matskevich AA, McKee HJ et al. What they are, how they work and why they do what they do? The story of SV40-derived gene therapy vectors and what they have to offer. Curr Gene Ther 2005; 5: 151-165.
14. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000; 97: 9180-9185.
15. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56: 1823-1827.
16. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-557.
17. Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM et al. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 1998; 16: 1345-1350.
18. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
19. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
20. Strayer DS. Gene therapy using SV40-derived vectors: what does the future hold? J Cell Physiol 1999; 181: 375-384.
21. Arad U, Ben-Nun-Shaul O, El-Latif MA, Nissim O, Oppenheim A. A new packaging cell line for SV40 vectors that eliminates the generation of T-antigen-positive, replication-competent recombinants. Virology 2002; 304: 155-159.
22. Cordelier P, Morse B, Strayer DS. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. Oligonucleotides 2003; 13: 281-294.
23. Strayer DS. SV40-based gene therapy vectors: turning an adversary into a friend. Curr Opin Mol Ther 2000; 2: 570-578.
24. Strayer DS, Lamothe M, Wei D, Milano J, Kondo R. Generation of recombinant SV40 vectors for gene transfer. Methods Mol Biol 2001; 165: 103-117.
25. Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 2002; 106: 81-88.
26. Vera M, Prieto J, Strayer DS, Fortes P. Factors influencing the production of recombinant SV40 vectors. Mol Ther 2004; 10: 780-791.
27. Shi L, Ho J, Norling LA, Roy M, Xu Y. A real time quantitative PCR-based method for the detection and quantification of simian virus 40. Biologicals 1999; 27: 241-252.
28. Gibbs RA. DNA amplification by the polymerase chain reaction. Anal Chem 1990; 62: 1202-1214.
29. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995; 92: 1580-1584.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
31. Rauly I, Saint-Laurent N, Delesque N, Buscail L, Esteve JP, Vaysse N et al. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. J Clin Invest 1996; 97: 1874-1883.
32. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002; 62: 6124-6131.
33. Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L et al. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 2005; 16: 1175-1193.
34. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G et al. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997; 57: 956-962.
35. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
36. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, McGregor F, Evans TR, Ganly I et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370-380.
37. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy 2002; 9: 30-37.
38. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Therapy 2002; 9: 1379-1386.
39. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Therapy 2001; 8: 568-578.
40. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001; 20: 7797-7803.
41. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55:3810-3816.
42. Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, Kitade Y et al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004; 6: 1139-1148.
43. Ndoye A, Merlin JL, Leroux A, Dolivet G, Erbacher P, Behr JP et al. Enhanced gene transfer and cell death following p53 gene transfer using photochemical internalisation of glucosylated PEI-DNA complexes. J Gene Med 2004; 6: 884-894.
44. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247.
45. Buchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Buchler MW et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003; 134: 772-782.
46. Chen LM, Le HY, Qin RY, Kumar M, Du ZY, Xia RJ et al. Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J Gastroenterol 2005; 11: 831-838.
47. Noro T, Miyake K, Suzuki-Miyake N, Igarashi T, Uchida E, Misawa T et al. Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res 2004; 64: 7486-7490.
48. Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, Yamamoto H et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 2003; 10: 771-778.
49. McClane SJ, Hamilton TE, DeMatteo RP, Burke C, Raper SE. Effect of adenoviral early genes and the host immune system on in vivo pancreatic gene transfer in the mouse. Pancreas 1997; 15: 236-245.
50. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
51. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 2002; 9: 513-521.
52. Cordelier P, Van Bockstaele E, Calarota SA, Strayer DS. Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. Mol Ther 2003; 7: 801-810.
53. Strayer DS. SV40 as an effective gene transfer vector in vivo. J Biol Chem 1996; 271: 24741-24746.
54. Strayer DS. Gene delivery to human hematopoietic progenitor cells to address inherited defects in the erythroid cellular lineage. J Hematother Stem Cell Res 1999; 8: 573-574.
55. Strayer DS. Effective gene transfer using viral vectors based on SV40. Methods Mol Biol 2000; 133: 61-74.
56. Strayer DS, Kondo R, Milano J, Duan LX. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Therapy 1997; 4: 219-225.
57. Strayer DS, Milano J. SV40 mediates stable gene transfer in vivo. Gene Therapy 1996; 3: 581-587.
58. Strayer DS, Zern MA. Gene delivery to the liver using simian virus 40-derived vectors. Semin Liver Dis 1999; 19: 71-81.
59. Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 2003; 100: 155-160.
60. Liu B, Daviau J, Nichols CN, Strayer DS. In vivo gene transfer into rat bone marrow progenitor cells using rSV40 viral vectors. Blood 2005; 106: 2655-2662.
61. Sauter BV, Parashar B, Chowdhury NR, Kadakol A, Ilan Y, Singh H et al. A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats. Gastroenterology 2000; 119: 1348-1357.
62. Duan YY, Wu J, Zhu JL, Liu SL, Ozaki I, Strayer DS et al. Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterology 2004; 127: 1222-1232.
63. Strayer D, Branco F, Zern MA, Yam P, Calarota SA, Nichols CN et al. Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol Ther 2002; 6: 227-237.
64. Pipas JM. Common and unique features of T antigens encoded by the polyomavirus group. J Virol 1992; 66: 3979-3985.
65. Schirmbeck R, von der Weth A, Deppert W. Structural requirements for simian virus 40 replication and virion maturation. J Virol 1993; 67: 894-901.
66. Baiker A, Maercker C, Piechaczek C, Schmidt SB, Bode J, Benham C et al. Mitotic stability of an episomal vector containing a human scaffold/matrix- attached region is provided by association with nuclear matrix. Nat Cell Biol 2000; 2: 182-184.
67. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999; 10: 995-1008.
68. Buscail L, Pages P, Berthelemy P, Fourtanier G, Frexinos J, Escourrou J. Role of EUS in the management of pancreatic and ampullary carcinoma:a prospective study assessing resectability and prognosis. Gastrointest Endosc 1999; 50: 34-40.
69. Costentin L, Pages P, Bouisson M, Berthelemy P, Buscail L, Escourrou J et al. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology 2002; 2: 17-25.
70. Kern SE. Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am 2000; 84: 691-695 xi.
71. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998; 7:25-41.